Rising Demand for Targeted Therapy Drives PARP Inhibitors Market is anticipated to approach US$ 8.43 Billion by 2026 | FMI

By 2022, it is anticipated that the PARP inhibitors market would reach US$ 5.51 billion. The market is expanding because to the rising need for sophisticated targeted therapy for the treatment of chronic illnesses like cancer.

According to Future Market Insights (FMI), during the projection period of 2022–2026, the demand for PARP inhibitors is anticipated to approach US$ 8.43 billion. This growth will be fueled by an excellent CAGR of 11.2%.

The incidence of breast cancer is much higher in these countries, and with superior efficacy of PARP inhibitors as compared to other available cancer treatment options, the PARP inhibitors market is expected to gain significant revenue over the forecast period.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

“The unique ability of PARP inhibitors to improve progression-free survival in ovarian and breast cancer patients is expected to generate extensive traction for the market, thereby propelling the growth of the global PARP inhibitors market over the forecast period.”

Key Takeaways of PARP Inhibitors Market Study

• Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2021, and will continue to do so during the forecast period.
• PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.
• With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.

Strategic Acquisitions & Collaborations by Key Players to Widen Regional Presence

All marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings.

For example, in January 2022, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).

Key Companies Profiled:

• AstraZeneca
• GlaxoSmithKline
• Merck Co. & Inc
• GlaxoSmithKline plc
• AbbVie Inc
• Clovis Oncology
• Medivation
• Johnson & Johnson Services, Inc
• Pfizer Inc.
• Repare Therapeutics, Inc.
• Genentech, Inc.
• Artios Pharma
• Repare Therapeutics Inc.
• Sierra Oncology, Inc.
• KaryopharmTherapeutics Inc.
• Ono Pharmaceutical Co., Ltd.
• Jiangsu Hengrui Medicine Co., Ltd.

PARP Inhibitors Market by Category By Drug Type:

• Olaparib
• Niraparib
• Rucaparib
• Talazoparib

By Indication:

• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube